6-K/A
2024-06-30false0001627281Q2--12-310001627281clls:CalyxtMember2024-01-012024-06-300001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:EstimatedFairValueMember2024-06-300001627281clls:BpifranceMemberclls:GrantAndRefundableAdvanceAgreementMember2023-04-012023-06-300001627281ifrs-full:SharePremiumMember2024-01-012024-06-300001627281clls:SAFreeSharesMember2024-01-012024-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMemberclls:LicenseAndCollaborationAgreementsMember2023-12-310001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2023-01-012023-06-300001627281clls:RiskFreeRateMember2023-11-140001627281clls:TrancheAWarrantsMember2023-04-172023-04-170001627281clls:StockOption1Member2023-01-012023-12-310001627281clls:AstraZenecaMember2023-11-140001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2023-12-310001627281clls:TrancheAWarrantsMemberclls:EuropeanInvestmentBankLoanMember2023-04-170001627281clls:MilestoneAchievementRelatedToDosingOfFirstSubjectInPhaseIMember2024-06-300001627281ifrs-full:LaterThanFiveYearsMember2023-12-310001627281ifrs-full:NoncontrollingInterestsMember2024-01-012024-06-300001627281ifrs-full:RightofuseAssetsMember2023-12-310001627281clls:TrancheBWarrantsMember2024-01-252024-01-250001627281clls:ForwardForeignExchangeRateMember2023-11-140001627281clls:LeasedEquipmentMemberstpr:NC2024-06-300001627281clls:CalyxtIncMember2023-06-012023-06-010001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-12-310001627281clls:TrancheAWarrantsMember2023-04-172024-06-300001627281clls:CibusIncMember2023-12-310001627281clls:CellectisSaMemberifrs-full:EquityAttributableToOwnersOfParentMember2023-01-012023-06-300001627281clls:AstraZenecaMemberifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:LeasedPremisesMemberstpr:NC2024-06-300001627281clls:ResearchTaxCreditFinancingMemberclls:OtherNonCurrentFinancialLiabilitiesMember2023-12-310001627281ifrs-full:ConstructionInProgressMember2024-06-300001627281clls:JointCollaborationAndResearchAgreementMember2024-01-012024-06-300001627281clls:SAFreeSharesMember2023-12-310001627281clls:StockOption1Member2022-01-012022-12-310001627281ifrs-full:LandAndBuildingsMember2024-01-012024-06-300001627281clls:EuropeanInvestmentBankLoanMember2023-04-170001627281clls:NonEmployeeWarrantsMember2024-01-012024-06-300001627281ifrs-full:RetainedEarningsMember2024-06-3000016272812024-03-050001627281clls:ClassAConvertiblePreferredSharesMember2023-11-140001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-3000016272812023-06-012023-06-300001627281clls:ResearchTaxCreditFinancingMemberclls:OtherNonCurrentFinancialLiabilitiesMember2023-08-310001627281ifrs-full:SharePremiumMember2023-12-310001627281clls:CapitalEvolution2024Member2024-05-2800016272812022-11-232022-11-230001627281clls:CellectisBiologicsIncMemberclls:CellectisIncMember2024-01-012024-06-300001627281clls:AstraZenecaMember2023-11-010001627281stpr:NYclls:OtherNonCurrentFinancialLiabilitiesMember2024-06-300001627281clls:StockOption1Member2023-12-310001627281ifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281clls:CapitalEvolution2024Member2024-05-120001627281country:FR2024-04-012024-06-3000016272812024-06-300001627281ifrs-full:NoncontrollingInterestsMember2024-06-300001627281country:FR2024-01-012024-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-06-300001627281ifrs-full:ConstructionInProgressMember2023-06-300001627281clls:InitialInvestmentAgreementMember2024-01-012024-06-300001627281clls:GrantAndRefundableAdvanceAgreementMember2023-03-082023-03-080001627281clls:PrimeraTherapeuticsIncMember2023-05-172023-05-170001627281clls:CarryingAmountAndValueMember2024-06-3000016272812023-11-140001627281clls:AccruedAndUnpaidInterestAccruedMemberclls:CytoviaAgreementMember2024-06-300001627281clls:StockOption1Member2023-01-012023-06-300001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-12-310001627281clls:ResearchTaxCreditFinancingMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-06-300001627281clls:LicenseAndCollaborationAgreementsMember2023-12-310001627281clls:ItLicensingAgreementsMember2024-06-300001627281clls:ResearchTaxCreditFinancingMemberclls:OtherNonCurrentFinancialLiabilitiesMember2022-06-300001627281clls:ForeignCitizensMemberclls:SAFreeSharesMember2024-01-012024-06-300001627281ifrs-full:RightofuseAssetsMember2023-01-012023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2024-06-300001627281clls:TrancheBWarrantsMember2024-01-252024-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-06-300001627281ifrs-full:NoncontrollingInterestsMember2022-12-310001627281clls:FrenchResidentEmployeesMemberclls:SAFreeSharesMember2024-01-012024-06-300001627281clls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:SubsequentInvestmentAgreementMemberclls:CapitalEvolution2024Member2024-06-300001627281clls:CellectisSaMember2023-01-012023-06-300001627281clls:JointResearchAndCollaborationAgreementMember2023-01-012023-12-310001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001627281clls:ProvisionForTaxLitigationMember2023-12-310001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:TopOfRangeMember2024-06-300001627281clls:TrancheAWarrantsMember2024-01-012024-06-300001627281clls:FrenchEmployeesMemberclls:SAFreeSharesMember2024-01-012024-06-300001627281clls:StateGuaranteedLoanMember2024-06-300001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001627281clls:TechnicalEquipmentsMember2023-12-310001627281clls:GrantAndRefundableAdvanceAgreementMemberifrs-full:AtFairValueMember2024-06-300001627281clls:ClinicalAndRdAgreementsMember2024-06-300001627281ifrs-full:EquityAttributableToOwnersOfParentMember2022-12-310001627281clls:GrantAndRefundableAdvanceAgreementMember2023-06-190001627281ifrs-full:RetainedEarningsMember2022-12-310001627281ifrs-full:RetainedEarningsMember2023-01-012023-06-300001627281clls:CurrencyTranslationAdjustmentMember2024-01-012024-06-300001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2023-06-300001627281clls:AstraZenecaMember2023-11-012023-11-010001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-12-310001627281ifrs-full:SharePremiumMember2022-12-310001627281clls:AstraZenecaMember2024-06-300001627281clls:JointCollaborationAndResearchAgreementMember2024-03-042024-03-040001627281clls:BpifranceMemberclls:GrantAndRefundableAdvanceAgreementMember2023-01-012023-06-300001627281clls:GrantAndRefundableAdvanceAgreementMember2024-01-012024-06-300001627281clls:PerformanceStockUnitMemberclls:CalyxtMember2023-01-012023-06-300001627281clls:SubsequentInvestmentAgreementMember2023-11-012023-11-010001627281clls:NonEmployeeWarrantsMember2023-01-012023-06-300001627281clls:AstraZenecaMember2024-05-030001627281clls:TrancheBWarrantsMember2024-01-242024-01-240001627281clls:ClinicalAndRdAgreementsMember2023-12-310001627281ifrs-full:NotLaterThanOneYearMember2024-06-300001627281clls:OtherProvisionForChargesMember2024-06-300001627281ifrs-full:TopOfRangeMemberclls:EquityAwardsMember2023-01-012023-06-300001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:EuropeanInvestmentBankLoanMember2022-12-280001627281clls:StockOption1Memberclls:CalyxtMember2023-01-012023-06-3000016272812024-01-012024-06-300001627281ifrs-full:EquityAttributableToOwnersOfParentMember2023-06-300001627281clls:AmendmentAgreementOneMemberclls:CytoviaAgreementMemberifrs-full:DebtSecuritiesMemberclls:CellectisMember2022-04-012022-04-300001627281country:US2023-04-012023-06-300001627281clls:CalyxtMember2023-05-312023-05-310001627281ifrs-full:BottomOfRangeMemberclls:EquityAwardsMember2024-01-012024-06-300001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001627281clls:EquityAwardsMember2024-01-012024-06-300001627281clls:CytoviaMember2023-12-310001627281clls:ClassBConvertiblePreferredSharesMember2023-11-140001627281clls:TrancheBWarrantsMember2024-01-240001627281clls:AstraZenecaMember2024-05-032024-05-030001627281ifrs-full:RetainedEarningsMember2023-12-310001627281clls:SAFreeSharesMember2023-06-300001627281clls:CommercialLitigationMember2023-12-310001627281clls:TechnicalEquipmentsMember2023-06-300001627281clls:ProvisionForTaxLitigationMember2024-06-300001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2023-12-310001627281clls:AmendmentAgreementOneMemberclls:CytoviaAgreementMemberifrs-full:DebtSecuritiesMemberclls:CellectisMember2022-04-300001627281clls:StateGuaranteedLoanMember2024-01-012024-06-300001627281clls:ItLicensingAgreementsMember2023-12-310001627281clls:SubsequentInvestmentAgreementMemberclls:CapitalEvolution2024Member2024-01-012024-06-300001627281ifrs-full:TopOfRangeMemberclls:EquityAwardsMember2024-01-012024-06-300001627281ifrs-full:SharePremiumMember2023-01-012023-06-300001627281clls:TrancheBWarrantsMember2024-06-300001627281clls:CellectisSaMember2024-01-012024-06-300001627281ifrs-full:BottomOfRangeMemberclls:EquityAwardsMember2023-01-012023-06-300001627281ifrs-full:SharePremiumMember2024-06-300001627281clls:VolatilityMember2023-11-140001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2023-04-172023-04-170001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2024-05-152024-05-150001627281clls:LicenseAndCollaborationAgreementsMember2024-06-300001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-252024-01-250001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2024-06-262024-06-2600016272812024-05-032024-05-030001627281clls:ProvisionForTaxLitigationMember2024-01-012024-06-300001627281ifrs-full:RightofuseAssetsMember2024-06-3000016272812023-04-012023-06-300001627281ifrs-full:ConstructionInProgressMember2024-01-012024-06-3000016272812024-05-030001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2024-06-300001627281clls:EmployeeLitigationAndSeveranceMember2024-01-012024-06-300001627281clls:TrancheBWarrantsMember2024-06-300001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2024-01-252024-01-250001627281clls:PersonnelExpensesMember2024-01-012024-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-06-300001627281clls:ResearchAndDevelopmentExpensesMember2024-01-012024-06-300001627281country:FR2023-04-012023-06-300001627281clls:SubsequentInvestmentAgreementMember2024-01-012024-06-300001627281clls:ClassBConvertiblePreferredSharesMemberclls:SubsequentInvestmentAgreementMemberclls:CapitalEvolution2024Member2024-06-300001627281clls:EquityAwardsMember2023-01-012023-06-300001627281clls:EmployeesMemberclls:SAFreeSharesMember2021-01-012021-12-310001627281ifrs-full:FixturesAndFittingsMember2024-06-300001627281ifrs-full:FixturesAndFittingsMember2024-01-012024-06-300001627281clls:CurrencyTranslationAdjustmentMember2022-12-310001627281clls:SAFreeSharesMember2024-06-300001627281clls:BpifranceMember2024-01-012024-06-300001627281clls:ForwardForeignExchangeRateMember2024-05-030001627281ifrs-full:LaterThanFiveYearsMemberclls:LicenseAndCollaborationAgreementsMember2024-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001627281clls:TrancheAWarrantsMember2024-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:TrancheBWarrantsMember2024-01-252024-01-250001627281clls:LicenseAndCollaborationAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001627281ifrs-full:OrdinarySharesMember2023-06-300001627281clls:CellectisSaMemberifrs-full:SharePremiumMember2023-01-012023-06-3000016272812023-06-3000016272812024-04-012024-06-3000016272812023-01-012023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2023-01-012023-06-300001627281clls:GrantAndRefundableAdvanceAgreementMember2023-03-080001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:CurrencyTranslationAdjustmentMember2023-12-310001627281clls:CalyxtIncMemberifrs-full:OrdinarySharesMember2023-05-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2023-12-310001627281clls:TechnicalEquipmentsMember2022-12-310001627281ifrs-full:EquityAttributableToOwnersOfParentMember2023-01-012023-06-300001627281clls:NonEmployeeWarrantsMember2024-06-300001627281clls:SubsequentInvestmentAgreementMember2023-11-010001627281ifrs-full:FixturesAndFittingsMember2023-12-310001627281ifrs-full:LaterThanFiveYearsMember2024-06-300001627281clls:PrimeraTherapeuticsIncMember2024-01-012024-06-300001627281clls:LicenseAndCollaborationAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-06-300001627281clls:CurrencyTranslationAdjustmentMember2023-06-300001627281ifrs-full:ConstructionInProgressMember2022-12-310001627281clls:StockOption1Memberclls:NonExecutiveEmployeesMember2024-06-262024-06-260001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2022-12-310001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:CalyxtMember2023-01-012023-06-300001627281clls:CarryingAmountAndValueMember2023-12-310001627281clls:CellectisIncMember2024-01-012024-06-300001627281clls:StockOption1Member2024-01-012024-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2023-04-012023-06-300001627281clls:SAFreeSharesMember2023-01-012023-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-12-310001627281clls:EmployeeLitigationAndSeveranceMember2024-06-300001627281ifrs-full:NotLaterThanOneYearMember2023-12-310001627281clls:NonEmployeeWarrantsMember2023-01-012023-12-310001627281clls:ClassACommonStockMemberclls:CibusGlobalLlcMember2023-05-310001627281clls:TrancheBWarrantsMember2024-01-012024-06-300001627281clls:ResearchAndDevelopmentExpensesMember2023-04-012023-06-300001627281ifrs-full:LandAndBuildingsMember2022-12-310001627281clls:AmendmentAgreementOneMemberclls:CytoviaAgreementMemberifrs-full:DebtSecuritiesMemberclls:CytoviaMemberclls:AmendedAndRestatedAgreementMemberclls:CellectisMember2023-02-012023-06-300001627281country:FR2023-01-012023-06-300001627281ifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-06-300001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2024-06-300001627281clls:ReinvoicingToAzIrelandOfResearchCostsRechargeableMember2024-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:NotLaterThanOneYearMember2024-06-300001627281ifrs-full:BottomOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281ifrs-full:OrdinarySharesMember2023-01-012023-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanFiveYearsMember2023-12-310001627281clls:RiskFreeRateMember2023-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-12-310001627281clls:SellingGeneralAndAdministrativeExpenses1Member2023-01-012023-06-300001627281clls:CalyxtIncMemberclls:ClassACommonStockMember2023-05-310001627281clls:CibusMember2024-04-012024-06-300001627281clls:LeasedPremisesMemberstpr:NY2024-06-300001627281clls:SAFreeSharesMember2022-12-310001627281clls:CellectisSaMemberifrs-full:SharePremiumMember2024-01-012024-06-300001627281clls:GrantAndRefundableAdvanceAgreementMember2023-10-060001627281clls:CalyxtMember2023-05-310001627281clls:AstraZenecaMemberifrs-full:SharePremiumMemberclls:CapitalEvolution2024Member2024-01-012024-06-300001627281ifrs-full:FixturesAndFittingsMember2022-12-310001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2024-06-300001627281clls:InitialInvestmentAgreementMember2023-11-012023-11-010001627281ifrs-full:NoncontrollingInterestsMember2023-01-012023-06-300001627281clls:OtherProvisionForChargesMember2023-12-310001627281clls:PensionMember2023-12-310001627281clls:AstraZenecaIrelandMember2024-01-012024-06-300001627281ifrs-full:OrdinarySharesMember2024-01-012024-06-300001627281clls:CurrencyTranslationAdjustmentMember2024-06-300001627281clls:JointCollaborationAndResearchAgreementMember2024-06-300001627281clls:ClassAConvertiblePreferredSharesMemberclls:SubsequentInvestmentAgreementMemberclls:CapitalEvolution2024Member2024-06-300001627281clls:EuropeanInvestmentBankLoanMember2024-01-250001627281clls:EmployeeLitigationAndSeveranceMember2023-12-310001627281clls:TrancheAWarrantsMember2023-12-310001627281ifrs-full:LandAndBuildingsMember2023-06-300001627281clls:TrancheAWarrantsMember2023-04-172023-12-310001627281clls:ItLicensingAgreementsMemberifrs-full:NotLaterThanOneYearMember2023-12-310001627281clls:ForwardForeignExchangeRateMember2023-12-310001627281clls:ResearchAndDevelopmentExpensesMember2024-04-012024-06-300001627281clls:NonEmployeeWarrantsMember2022-01-012022-12-310001627281clls:CalyxtAtmProgramMemberclls:CellectisIncMember2023-05-312023-05-310001627281ifrs-full:RightofuseAssetsMember2023-01-012023-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:BottomOfRangeMember2024-06-300001627281clls:AstraZenecaMember2023-12-310001627281ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-06-300001627281clls:StateGuarantedLoanMember2023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2023-06-300001627281ifrs-full:RetainedEarningsMember2024-01-012024-06-300001627281clls:CibusMember2024-01-012024-06-300001627281clls:GrantedInTwoThousandAndTwentyOneMemberclls:ExecutiveOfficersMemberclls:SAFreeSharesMember2021-01-012021-12-310001627281clls:CytoviaAgreementMemberclls:CellectisMember2021-10-012021-12-310001627281ifrs-full:NoncontrollingInterestsMember2023-06-300001627281ifrs-full:LandAndBuildingsMember2023-12-310001627281clls:CytoviaAgreementMemberclls:PrincipalMember2024-06-300001627281clls:CellectisSaMemberifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-06-300001627281ifrs-full:EquityAttributableToOwnersOfParentMember2023-12-310001627281clls:TrancheAWarrantsMember2023-04-172023-04-170001627281clls:CytoviaMember2024-06-300001627281clls:CytoviaAgreementMemberclls:ConvertibleNotesMemberclls:CytoviaMember2024-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-04-012024-06-3000016272812023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2022-12-310001627281clls:EuropeanInvestmentBankLoanMember2024-01-012024-06-300001627281clls:InitialInvestmentAgreementMember2023-11-010001627281ifrs-full:ConstructionInProgressMember2023-01-012023-06-300001627281ifrs-full:LandAndBuildingsMember2024-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281ifrs-full:OrdinarySharesMember2024-06-300001627281clls:ExecutiveOfficersMemberclls:SAFreeSharesMember2024-01-012024-06-300001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2024-06-300001627281ifrs-full:ConstructionInProgressMember2023-12-310001627281ifrs-full:SharePremiumMember2023-06-300001627281country:US2024-01-012024-06-300001627281clls:CurrencyTranslationAdjustmentMember2023-01-012023-06-300001627281ifrs-full:RetainedEarningsMember2023-06-300001627281clls:Alpha2ClinicalTrialServierLicenseAgreementMember2024-01-012024-06-300001627281clls:TechnicalEquipmentsMember2023-01-012023-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMemberclls:LicenseAndCollaborationAgreementsMember2024-06-300001627281clls:TechnicalEquipmentsMember2024-06-3000016272812023-11-142023-11-1400016272812022-12-310001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-250001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-06-300001627281clls:NonEmployeeWarrantsMember2023-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2023-12-310001627281ifrs-full:NotLaterThanOneYearMemberclls:LicenseAndCollaborationAgreementsMember2024-06-300001627281country:US2024-04-012024-06-300001627281clls:PensionMember2024-06-300001627281clls:TrancheAWarrantsMember2024-06-300001627281clls:CalyxtMember2023-04-242023-04-240001627281ifrs-full:LaterThanFiveYearsMemberclls:LicenseAndCollaborationAgreementsMember2023-12-310001627281ifrs-full:NotLaterThanOneYearMemberclls:LicenseAndCollaborationAgreementsMember2023-12-310001627281clls:NonEmployeeWarrantsMember2022-12-310001627281clls:GrantAndRefundableAdvanceAgreementMemberifrs-full:AtFairValueMember2024-01-012024-06-300001627281clls:ItLicensingAgreementsMemberifrs-full:LaterThanFiveYearsMember2024-06-300001627281clls:EstimatedFairValueMember2023-12-310001627281ifrs-full:RightofuseAssetsMember2022-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2023-12-310001627281clls:CalyxtMember2023-05-312023-05-310001627281clls:AstraZenecaMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:RestrictedStockUnitMember2023-01-012023-06-300001627281ifrs-full:FixturesAndFittingsMember2023-01-012023-06-300001627281ifrs-full:OrdinarySharesMember2022-12-310001627281clls:StockOption1Member2023-06-300001627281clls:PersonnelExpensesMember2023-01-012023-06-300001627281clls:PersonnelExpensesMember2023-04-012023-06-300001627281clls:PersonnelExpensesMember2024-04-012024-06-300001627281clls:OtherProvisionForChargesMember2024-01-012024-06-300001627281clls:StockOption1Member2022-12-310001627281ifrs-full:OfficeEquipmentMemberifrs-full:RightofuseAssetsMember2024-01-012024-06-300001627281clls:TrancheAWarrantsMemberclls:EuropeanInvestmentBankLoanMember2023-04-172023-04-170001627281clls:PensionMember2024-01-012024-06-300001627281clls:CommercialLitigationMember2024-06-300001627281clls:CapitalEvolution2024Member2024-03-050001627281ifrs-full:FixturesAndFittingsMember2023-06-300001627281clls:CibusIncMember2024-06-300001627281clls:NonEmployeeWarrantsMember2023-12-310001627281clls:StateGuarantedLoanMember2024-06-300001627281clls:CibusGlobalLlcMember2023-06-012023-06-010001627281ifrs-full:EquityAttributableToOwnersOfParentMember2024-06-3000016272812023-01-012023-06-300001627281clls:TechnicalEquipmentsMember2024-01-012024-06-300001627281clls:StockOption1Member2024-06-300001627281ifrs-full:LandAndBuildingsMember2023-01-012023-06-300001627281ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2024-01-012024-06-300001627281ifrs-full:OrdinarySharesMember2023-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2024-06-300001627281clls:PrimeraTherapeuticsIncMember2022-12-292022-12-290001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-01-012024-06-300001627281country:US2023-01-012023-06-3000016272812023-06-012024-06-300001627281clls:CommercialLitigationMember2024-01-012024-06-300001627281ifrs-full:RightofuseAssetsMember2023-06-300001627281ifrs-full:RightofuseAssetsMember2024-01-012024-06-300001627281clls:CapitalEvolution2024Member2024-01-012024-06-300001627281clls:ResearchAndDevelopmentExpensesMember2023-01-012023-06-30iso4217:EURclls:Productclls:Cellxbrli:pureiso4217:EURxbrli:sharesxbrli:sharesclls:Warrantsclls:Optionsiso4217:USDclls:SegmentUnit
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
Amendment No. 1 to Report on Form 6-K (Film No. 241179819)
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date of Report: September 11, 2024
Commission File Number: 001-36891
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Explanatory Note
This report on Form 6-K/A (this “Amendment”) filed by Cellectis S.A. (the “Company”) amends the Company’s report on Form 6-K, which included the Company’s unaudited Condensed Consolidated Interim Financial Statements as of, and for the three- and six-month periods ended, June 30, 2024 (the “Report”), filed with the U.S. Securities and Exchange Commission on August 6, 2024, solely to provide the financial statements formatted in iXBRL (Inline eXtensible Business Reporting Language) in accordance with Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of the General Instructions to Form 6-K. Exhibit 101 includes information in Inline eXtensible Business Reporting Language.
Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, revise, update or restate the information presented in the Report or reflect any events that have occurred after the Report was originally filed.
Cellectis S.A.
The following document, which is attached as an exhibit hereto, is incorporated by reference herein.
The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of Cellectis S.A. on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760 and 333-273777), to the extent not superseded by documents or reports subsequently filed.
EXHIBIT INDEX
101 The following materials from Cellectis S.A.’s Report on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Financial Position, (ii) the Condensed Consolidated Statements of Operations (Unaudited), (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Cash Flow (Unaudited), (v) the Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited), and (vi) the Notes to the Interim Consolidated Financial Statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
CELLECTIS S.A. (Registrant) |
|
|
|
September 11, 2024 |
By: |
/s/ André Choulika |
|
|
André Choulika |
|
|
Chief Executive Officer |